-
1
-
-
0002645703
-
Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo
-
Flanagan, A.D.; Love, R.; Tesar, W. Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo. Proc. Soc. Exp. Biol. Med. 1955, 90, 82-86.
-
(1955)
Proc. Soc. Exp. Biol. Med
, vol.90
, pp. 82-86
-
-
Flanagan, A.D.1
Love, R.2
Tesar, W.3
-
2
-
-
84901298894
-
-
The U.S. Food Drug Administration (FDA). Available online: (accessed on 15 March 2012)
-
The U.S. Food Drug Administration (FDA). Available online: http://www.fda.gov/Biologics BloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210012.htm/ (accessed on 15 March 2012).
-
-
-
-
3
-
-
0001588880
-
Historical aspects
-
In, Alexander, D.J., Ed.; Kluwer Academic: Boston, MA, USA
-
Alexander, D.J. Historical aspects. In Newcastle Disease; Alexander, D.J., Ed.; Kluwer Academic: Boston, MA, USA, 1988; pp. 1-10.
-
(1988)
Newcastle Disease
, pp. 1-10
-
-
Alexander, D.J.1
-
4
-
-
0006187648
-
A hitherto unrecorded disease of fowls due to a filter-passing virus
-
Doyle, T.M. A hitherto unrecorded disease of fowls due to a filter-passing virus. J. Comp. Pathol. Ther. 1927, 40, 144-169.
-
(1927)
J. Comp. Pathol. Ther.
, vol.40
, pp. 144-169
-
-
Doyle, T.M.1
-
5
-
-
0032947017
-
Complete nucleotide sequence of Newcastle disease virus: Evidence for the existence of a new genus within the subfamily Paramyxovirinae
-
De Leeuw, O.; Peeters, B. Complete nucleotide sequence of Newcastle disease virus: Evidence for the existence of a new genus within the subfamily Paramyxovirinae. J. Gen. Virol. 1999, 80, 131-136.
-
(1999)
J. Gen. Virol.
, vol.80
, pp. 131-136
-
-
De Leeuw, O.1
Peeters, B.2
-
6
-
-
84865794631
-
α2-3-and α2-6-N-linked sialic acids allow efficient interaction of Newcastle Disease Virus with target cells
-
Sánchez-Felipe, L.; Villar, E.; Muñoz-Barroso, I. α2-3-and α2-6-N-linked sialic acids allow efficient interaction of Newcastle Disease Virus with target cells. Glycoconj. J. 2012, 29, 539-549.
-
(2012)
Glycoconj. J.
, vol.29
, pp. 539-549
-
-
Sánchez-Felipe, L.1
Villar, E.2
Muñoz-Barroso, I.3
-
7
-
-
84861303416
-
The second receptor binding site of the globular head of the Newcastle disease virus hemagglutinin-neuraminidase activates the stalk of multiple paramyxovirus receptor binding proteins to trigger fusion
-
Porotto, M.; Salah, Z.; DeVito, I.; Talekar, A.; Palmer, S.G.; Xu, R.; Wilson, I.A.; Moscona, A. The second receptor binding site of the globular head of the Newcastle disease virus hemagglutinin-neuraminidase activates the stalk of multiple paramyxovirus receptor binding proteins to trigger fusion. J. Virol. 2012, 86, 5730-5741.
-
(2012)
J. Virol.
, vol.86
, pp. 5730-5741
-
-
Porotto, M.1
Salah, Z.2
DeVito, I.3
Talekar, A.4
Palmer, S.G.5
Xu, R.6
Wilson, I.A.7
Moscona, A.8
-
8
-
-
84862813177
-
Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication
-
Meng, C.; Zhou, Z.; Jiang, K.; Yu, S.; Jia, L.; Wu, Y.; Liu, Y.; Meng, S.; Ding, C. Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication. Arch. Virol. 2012, 8, 1011-1018.
-
(2012)
Arch. Virol.
, vol.8
, pp. 1011-1018
-
-
Meng, C.1
Zhou, Z.2
Jiang, K.3
Yu, S.4
Jia, L.5
Wu, Y.6
Liu, Y.7
Meng, S.8
Ding, C.9
-
9
-
-
0024835436
-
Molecular biology of Newcastle disease virus
-
Nagai, Y.; Hamaguchi, M.; Toyoda, T. Molecular biology of Newcastle disease virus. Prog. Vet. Microbiol. Immunol. 1989, 5, 16-64.
-
(1989)
Prog. Vet. Microbiol. Immunol
, vol.5
, pp. 16-64
-
-
Nagai, Y.1
Hamaguchi, M.2
Toyoda, T.3
-
10
-
-
67650340774
-
Newcastle disease virus: A promising vector for viral therapy, immune therapy, and gene therapy of cancer
-
Schirrmacher, V.; Fournier, P. Newcastle disease virus: A promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol. Biol. 2009, 542, 565-605.
-
(2009)
Methods Mol. Biol.
, vol.542
, pp. 565-605
-
-
Schirrmacher, V.1
Fournier, P.2
-
11
-
-
0036905014
-
RNA viruses as virotherapy agents
-
Russell, S.J. RNA viruses as virotherapy agents. Cancer Gene Ther. 2002, 9, 961-966.
-
(2002)
Cancer Gene Ther.
, vol.9
, pp. 961-966
-
-
Russell, S.J.1
-
12
-
-
33745206950
-
Tumor-selective replication of Newcastle Disease Virus: Association with defects of tumor cells defence
-
Fiola, C.; Peeters, B.; Fournier, P.; Arnold, A.; Bucur, M.; Schirrmacher, V. Tumor-selective replication of Newcastle Disease Virus: Association with defects of tumor cells defence. Int. J. Cancer 2006, 119, 328-338.
-
(2006)
Int. J. Cancer
, vol.119
, pp. 328-338
-
-
Fiola, C.1
Peeters, B.2
Fournier, P.3
Arnold, A.4
Bucur, M.5
Schirrmacher, V.6
-
13
-
-
0026751242
-
Newcastle disease virus selectively kills human tumor cells
-
Reichard, K.W.; Lorence, R.M.; Cascino, C.J.; Peeples, M.E.; Walter, R.J.; Fernando, M.B.; Reyes, H.M.; Greager, J.A. Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 1992, 52, 448-453.
-
(1992)
J. Surg. Res.
, vol.52
, pp. 448-453
-
-
Reichard, K.W.1
Lorence, R.M.2
Cascino, C.J.3
Peeples, M.E.4
Walter, R.J.5
Fernando, M.B.6
Reyes, H.M.7
Greager, J.A.8
-
14
-
-
33646752347
-
Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines
-
Krishnamurthy, S.; Takimoto, T.; Scroggs, R.A.; Portner, A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J. Virol. 2006, 80, 5145-5155.
-
(2006)
J. Virol.
, vol.80
, pp. 5145-5155
-
-
Krishnamurthy, S.1
Takimoto, T.2
Scroggs, R.A.3
Portner, A.4
-
15
-
-
67649421085
-
Expression of RIG-I, IRF3, IFN-β and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus
-
Wilden, H.; Fournier, P.; Zawatzky, R.; Schirrmacher, V. Expression of RIG-I, IRF3, IFN-β and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Int. J. Oncol. 2009, 34, 971-982.
-
(2009)
Int. J. Oncol.
, vol.34
, pp. 971-982
-
-
Wilden, H.1
Fournier, P.2
Zawatzky, R.3
Schirrmacher, V.4
-
16
-
-
84455193926
-
Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
-
Fournier, P.; Wilden, H.; Schirrmacher, V. Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. Int. J. Oncol. 2012, 40, 287-298.
-
(2012)
Int. J. Oncol.
, vol.40
, pp. 287-298
-
-
Fournier, P.1
Wilden, H.2
Schirrmacher, V.3
-
17
-
-
3242813113
-
The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate anti-viral responses
-
Yoneyama, M.; Kikuchi, M.; Natsukawa, T.; Shinobu, N.; Imaizumi, T.; Biyagishi, M.; Taira, K.; Akira, S.; Fujita, T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate anti-viral responses. Nat. Immunol. 2004, 5, 730-737.
-
(2004)
Nat. Immunol.
, vol.5
, pp. 730-737
-
-
Yoneyama, M.1
Kikuchi, M.2
Natsukawa, T.3
Shinobu, N.4
Imaizumi, T.5
Biyagishi, M.6
Taira, K.7
Akira, S.8
Fujita, T.9
-
18
-
-
79960765634
-
Sensing of viral nucleic acids by RIG-I: From translocation to translation
-
Schmidt, A.; Rothenfusser, S.; Hopfner, K.P. Sensing of viral nucleic acids by RIG-I: From translocation to translation. Eur. J. Cell Biol. 2012, 91, 78-85.
-
(2012)
Eur. J. Cell Biol.
, vol.91
, pp. 78-85
-
-
Schmidt, A.1
Rothenfusser, S.2
Hopfner, K.P.3
-
19
-
-
26444539685
-
Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner
-
Melchjorsen, J.; Jensen, S.B.; Malmgaard, L.; Rasmussen, S.B.; Weber, F.; Bowie, A.G.; Matikainen, S.; Paludan, S.R. Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner. J. Virol. 2005, 79, 12944-12951.
-
(2005)
J. Virol.
, vol.79
, pp. 12944-12951
-
-
Melchjorsen, J.1
Jensen, S.B.2
Malmgaard, L.3
Rasmussen, S.B.4
Weber, F.5
Bowie, A.G.6
Matikainen, S.7
Paludan, S.R.8
-
20
-
-
33744791510
-
Essential role of MDA-5 in type 1 IFN responses to polyriboinosinic: Polyribocytidylic acid and encephalomyocarditis picornavirus
-
Gitlin, L.; Barchet, W.; Gilfillan, S.; Cella, M.; Beutler, B.; Flavell, R.A.; Diamond, M.S.; Colonna, M. Essential role of MDA-5 in type 1 IFN responses to polyriboinosinic: Polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl. Acad. Sci. USA 2006, 103, 8459-8464.
-
(2006)
Proc. Natl. Acad. Sci. USA
, vol.103
, pp. 8459-8464
-
-
Gitlin, L.1
Barchet, W.2
Gilfillan, S.3
Cella, M.4
Beutler, B.5
Flavell, R.A.6
Diamond, M.S.7
Colonna, M.8
-
21
-
-
33750976374
-
5'-Triphosphate RNA is the ligand for RIG-I
-
Hornung, V.; Ellegast, J.; Kim, S.; Brzózka, K.; Jung, A.; Kato, H.; Poeck, H.; Akira, S.; Conzelmann, K.K.; Schlee, M.; Endres, S.; Hartmann, G. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314, 994-997.
-
(2006)
Science
, vol.314
, pp. 994-997
-
-
Hornung, V.1
Ellegast, J.2
Kim, S.3
Brzózka, K.4
Jung, A.5
Kato, H.6
Poeck, H.7
Akira, S.8
Conzelmann, K.K.9
Schlee, M.10
Endres, S.11
Hartmann, G.12
-
22
-
-
33947518195
-
RIG-I: Tri-ing to discriminate between self and non-self RNA
-
Bowie, A.G.; Fitzgerald, K.A. RIG-I: Tri-ing to discriminate between self and non-self RNA. Trends Immunol. 2007, 28, 147-150.
-
(2007)
Trends Immunol.
, vol.28
, pp. 147-150
-
-
Bowie, A.G.1
Fitzgerald, K.A.2
-
23
-
-
0036467492
-
The interferon-α/β system in anti-viral responses: A multimodal machinery of gene regulation by the IRF family of transcription factors
-
Taniguchi, T.; Takaoka, A. The interferon-α/β system in anti-viral responses: A multimodal machinery of gene regulation by the IRF family of transcription factors. Curr. Opin. Immunol. 2002, 14, 111-116.
-
(2002)
Curr. Opin. Immunol.
, vol.14
, pp. 111-116
-
-
Taniguchi, T.1
Takaoka, A.2
-
24
-
-
32644464262
-
IRF family proteins and type 1 interferon induction in dendritic cells
-
Tailor, P.; Tamura, T.; Ozato, K. IRF family proteins and type 1 interferon induction in dendritic cells. Cell Res. 2006, 16, 134-140.
-
(2006)
Cell Res.
, vol.16
, pp. 134-140
-
-
Tailor, P.1
Tamura, T.2
Ozato, K.3
-
25
-
-
0001166016
-
Replication-competent, oncolytic Newcastle disease virus for cancer therapy
-
In, Hern aiz Driever, P., Rabkin, S.D., Eds.; Karger: Basel, Switzerland
-
Lorence, R.M.; Roberts, M.S.; Groene, W.S.; Rabin, H. Replication-competent, oncolytic Newcastle disease virus for cancer therapy. In Replication-competent Viruses for Cancer Therapy. Monographs in Virology; Hern aiz Driever, P., Rabkin, S.D., Eds.; Karger: Basel, Switzerland, 2001; Volume 22, pp. 160-182.
-
(2001)
Replication-competent Viruses for Cancer Therapy. Monographs in Virology
, vol.22
, pp. 160-182
-
-
Lorence, R.M.1
Roberts, M.S.2
Groene, W.S.3
Rabin, H.4
-
26
-
-
34547601896
-
Paramyxoviridae: Their viruses and their replication
-
In, 5th ed.; Knipe, D.M., Howley, P.M., Eds.; Wolters Kluwer/Lippincott Williams & Wilkins: Philadelphia, PA, USA
-
Lamb, R.A.; Parks, G.D. Paramyxoviridae: Their viruses and their replication. In Fields Virology, 5th ed.; Knipe, D.M., Howley, P.M., Eds.; Wolters Kluwer/Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007; pp. 1449-1496.
-
(2007)
Fields Virology
, pp. 1449-1496
-
-
Lamb, R.A.1
Parks, G.D.2
-
27
-
-
0033955837
-
Newcastle disease virus (NDV): Brief history of its oncolytic strains
-
Sinkovics, J.G.; Horvath, J.C. Newcastle disease virus (NDV): Brief history of its oncolytic strains. J. Clin. Virol. 2000, 16, 1-15.
-
(2000)
J. Clin. Virol.
, vol.16
, pp. 1-15
-
-
Sinkovics, J.G.1
Horvath, J.C.2
-
28
-
-
0035350835
-
Anti-tumor effects of Newcastle Disease Virus in vivo: Local versus systemic effects
-
Schirrmacher, V.; Griesbach, A.; Ahlert, T. Anti-tumor effects of Newcastle Disease Virus in vivo: Local versus systemic effects. Int. J. Oncol. 2001, 18, 945-952.
-
(2001)
Int. J. Oncol.
, vol.18
, pp. 945-952
-
-
Schirrmacher, V.1
Griesbach, A.2
Ahlert, T.3
-
29
-
-
38449106720
-
Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application
-
Apostolidis, L.; Schirrmacher, V.; Fournier, P. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int. J. Oncol. 2007, 31, 1009-1019.
-
(2007)
Int. J. Oncol.
, vol.31
, pp. 1009-1019
-
-
Apostolidis, L.1
Schirrmacher, V.2
Fournier, P.3
-
30
-
-
61449209742
-
Newcastle disease virus-induced cytopathic effect in infected cells is caused by apoptosis
-
Ravindra, P.V.; Tiwari, A.K.; Ratta, B.; Chaturvedi, U.; Palia, S.K.; Chauhan, R.S. Newcastle disease virus-induced cytopathic effect in infected cells is caused by apoptosis. Virus Res. 2009, 141, 13-20.
-
(2009)
Virus Res.
, vol.141
, pp. 13-20
-
-
Ravindra, P.V.1
Tiwari, A.K.2
Ratta, B.3
Chaturvedi, U.4
Palia, S.K.5
Chauhan, R.S.6
-
31
-
-
33746210139
-
Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death
-
Elankumaran, S.; Rockemann, D.; Samal, S.K. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J. Virol. 2006, 80, 7522-7534.
-
(2006)
J. Virol.
, vol.80
, pp. 7522-7534
-
-
Elankumaran, S.1
Rockemann, D.2
Samal, S.K.3
-
32
-
-
84866364621
-
Velogenic newcastle disease virus as an oncolytic virotherapeutics: In vitro characterization
-
Kumar, R.; Tiwari, A.K.; Chaturvedi, U.; Kumar, G.R.; Sahoo, A.P.; Rajmani, R.S.; Saxena, L.; Saxena, S.; Tiwari, S.; Kumar, S. Velogenic newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization. Appl. Biochem. Biotechnol. 2012, 167, 2005-2022.
-
(2012)
Appl. Biochem. Biotechnol.
, vol.167
, pp. 2005-2022
-
-
Kumar, R.1
Tiwari, A.K.2
Chaturvedi, U.3
Kumar, G.R.4
Sahoo, A.P.5
Rajmani, R.S.6
Saxena, L.7
Saxena, S.8
Tiwari, S.9
Kumar, S.10
-
33
-
-
34250308322
-
Apoptosis: A review of programmed cell death
-
Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495-516.
-
(2007)
Toxicol. Pathol.
, vol.35
, pp. 495-516
-
-
Elmore, S.1
-
34
-
-
84865520382
-
NDV-induced apoptosis in absence of Bax; evidence of involvement of apoptotic proteins upstream of mitochondria
-
Molouki, A.; Yusoff, K. NDV-induced apoptosis in absence of Bax; evidence of involvement of apoptotic proteins upstream of mitochondria. Virol. J. 2012, 9, 179.
-
(2012)
Virol. J.
, vol.9
, pp. 179
-
-
Molouki, A.1
Yusoff, K.2
-
35
-
-
84880244328
-
The oncolytic activity of newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: The interplay between VHL and interferon-β signaling
-
doi:10.1089/jir.2012.0095
-
Ch'ng, W.C.; Stanbridge, E.J.; Yusoff, K.; Shafee, N. The oncolytic activity of newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: The interplay between VHL and interferon-β signaling. J. Interferon Cytokine Res. 2013, doi:10.1089/jir.2012.0095.
-
(2013)
J. Interferon Cytokine Res.
-
-
Ch'ng, W.C.1
Stanbridge, E.J.2
Yusoff, K.3
Shafee, N.4
-
36
-
-
39049178459
-
In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein
-
Bian, H.; Wilden, H.; Fournier, P.; Peeters, B.; Schirrmacher, V. In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein. Int. J. Oncol. 2006, 29, 1359-1369.
-
(2006)
Int. J. Oncol.
, vol.29
, pp. 1359-1369
-
-
Bian, H.1
Wilden, H.2
Fournier, P.3
Peeters, B.4
Schirrmacher, V.5
-
37
-
-
0025043816
-
Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns
-
Ahlert, T.; Schirrmacher, V. Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns. Cancer Res. 1990, 50, 5962-5968.
-
(1990)
Cancer Res.
, vol.50
, pp. 5962-5968
-
-
Ahlert, T.1
Schirrmacher, V.2
-
38
-
-
0032897339
-
Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle Disease Virus
-
Schirrmacher, V.; Haas, C.; Bonifer, R.; Ahlert, T.; Gerhards, R.; Ertel, C. Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle Disease Virus. Gene Ther. 1999, 6, 63-73.
-
(1999)
Gene Ther.
, vol.6
, pp. 63-73
-
-
Schirrmacher, V.1
Haas, C.2
Bonifer, R.3
Ahlert, T.4
Gerhards, R.5
Ertel, C.6
-
39
-
-
0031674910
-
Immunization with virus-modified tumor cells
-
Schirrmacher, V.; Ahlert, T.; Pröbstle, T.; Steiner, H.H.; Herold-Mende, C.; Gerhards, R.; Hagmüller, E.; Steiner, H.H. Immunization with virus-modified tumor cells. Semin. Oncol. 1998, 25, 677-696.
-
(1998)
Semin. Oncol.
, vol.25
, pp. 677-696
-
-
Schirrmacher, V.1
Ahlert, T.2
Pröbstle, T.3
Steiner, H.H.4
Herold-Mende, C.5
Gerhards, R.6
Hagmüller, E.7
Steiner, H.H.8
-
40
-
-
0027484174
-
Viral hemagglutinin augments peptide-specific cytotoxic T cell responses
-
Ertel, C.; Millar, N.S.; Emmerson, P.T.; Schirrmacher, V.; von Hoegen, P. Viral hemagglutinin augments peptide-specific cytotoxic T cell responses. Eur. J. Immunol. 1993, 23, 2592-2596.
-
(1993)
Eur. J. Immunol.
, vol.23
, pp. 2592-2596
-
-
Ertel, C.1
Millar, N.S.2
Emmerson, P.T.3
Schirrmacher, V.4
von Hoegen, P.5
-
41
-
-
0036654058
-
Human tumor cell infection by Newcastle Disease Virus leads to up-regulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis
-
Washburn, B.; Schirrmacher, V. Human tumor cell infection by Newcastle Disease Virus leads to up-regulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int. J. Oncol. 2002, 21, 85-93.
-
(2002)
Int. J. Oncol.
, vol.21
, pp. 85-93
-
-
Washburn, B.1
Schirrmacher, V.2
-
42
-
-
0030725442
-
The double-stranded RNA-dependent protein kinase PKR: Structure and function
-
Clemens, M.J.; Elia, A. The double-stranded RNA-dependent protein kinase PKR: Structure and function. J. Interferon Cytokine Res. 1997, 17, 503-524.
-
(1997)
J. Interferon Cytokine Res.
, vol.17
, pp. 503-524
-
-
Clemens, M.J.1
Elia, A.2
-
43
-
-
22544455673
-
Cell type-specific involvement of RIG-I in anti-viral response
-
Kato, H.; Sato, S.; Yoneyama, M.; Yamamoto, M.; Uematsu, S.; Matsui, K.; Tsujimura, T.; Takeda, K.; Fujita, T.; Takeuchi, O.; et al. Cell type-specific involvement of RIG-I in anti-viral response. Immunity 2005, 23, 19-28.
-
(2005)
Immunity
, vol.23
, pp. 19-28
-
-
Kato, H.1
Sato, S.2
Yoneyama, M.3
Yamamoto, M.4
Uematsu, S.5
Matsui, K.6
Tsujimura, T.7
Takeda, K.8
Fujita, T.9
Takeuchi, O.10
-
44
-
-
0035909372
-
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3
-
Alexopoulou, L.; Holt, A.C.; Medzhitov, R.; Flavell, R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413, 732-738.
-
(2001)
Nature
, vol.413
, pp. 732-738
-
-
Alexopoulou, L.1
Holt, A.C.2
Medzhitov, R.3
Flavell, R.A.4
-
45
-
-
0036019520
-
Stimulation of human natural interferon-α and tumor necrosis factor-related paramyxovirus hemagglutinin lectin-cell interaction
-
Zeng, J.; Fournier, P.; Schirrmacher, V. Stimulation of human natural interferon-α and tumor necrosis factor-related paramyxovirus hemagglutinin lectin-cell interaction. J. Mol. Med. (Berl.) 2002, 80, 443-451.
-
(2002)
J. Mol. Med. (Berl.)
, vol.80
, pp. 443-451
-
-
Zeng, J.1
Fournier, P.2
Schirrmacher, V.3
-
46
-
-
0036302403
-
Induction of interferon-α and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus
-
Zeng, J.; Fournier, P.; Schirrmacher, V. Induction of interferon-α and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology 2002, 297, 19-30.
-
(2002)
Virology
, vol.297
, pp. 19-30
-
-
Zeng, J.1
Fournier, P.2
Schirrmacher, V.3
-
47
-
-
36348967103
-
Recombinant Newcastle Disease Virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
-
Janke, M.; Peeters, B.; de Leeuw, O.; Moorman, R.; Arnold, A.; Fournier, P.; Schirrmacher, V. Recombinant Newcastle Disease Virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther. 2007, 14, 1639-1649.
-
(2007)
Gene Ther.
, vol.14
, pp. 1639-1649
-
-
Janke, M.1
Peeters, B.2
de Leeuw, O.3
Moorman, R.4
Arnold, A.5
Fournier, P.6
Schirrmacher, V.7
-
48
-
-
0037441854
-
TNF-related apoptosis-inducing ligand mediated tumoricidal activity of human monocytes stimulated by Newcastle Disease Virus
-
Washburn, B.; Weigand, M.A.; Grosse-Wilde, A.; Janke, M.; Stahl, H.; Rieser, E.; Sprick, M.R.; Schirrmacher, V.; Walczak, H. TNF-related apoptosis-inducing ligand mediated tumoricidal activity of human monocytes stimulated by Newcastle Disease Virus. J. Immunol. 2003, 170, 1814-1821.
-
(2003)
J. Immunol.
, vol.170
, pp. 1814-1821
-
-
Washburn, B.1
Weigand, M.A.2
Grosse-Wilde, A.3
Janke, M.4
Stahl, H.5
Rieser, E.6
Sprick, M.R.7
Schirrmacher, V.8
Walczak, H.9
-
49
-
-
0036780171
-
Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients
-
Bai, L.; Koopmann, J.; Fiola, C.; Fournier, P.; Schirrmacher, V. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int. J. Oncol. 2002, 21, 685-694.
-
(2002)
Int. J. Oncol.
, vol.21
, pp. 685-694
-
-
Bai, L.1
Koopmann, J.2
Fiola, C.3
Fournier, P.4
Schirrmacher, V.5
-
50
-
-
67749124472
-
Activation of natural killer cells by Newcastle Disease Virus hemagglutinin-neuraminidase
-
Jarahian, M.; Watzl, C.; Fournier, P.; Arnold, A.; Djandji, D.; Zahedi, S.; Cerwenka, A.; Paschen, A.; Schirrmacher, V.; Momburg, F. Activation of natural killer cells by Newcastle Disease Virus hemagglutinin-neuraminidase. J. Virol. 2009, 83, 8108-8121.
-
(2009)
J. Virol.
, vol.83
, pp. 8108-8121
-
-
Jarahian, M.1
Watzl, C.2
Fournier, P.3
Arnold, A.4
Djandji, D.5
Zahedi, S.6
Cerwenka, A.7
Paschen, A.8
Schirrmacher, V.9
Momburg, F.10
-
51
-
-
0025274375
-
Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-α/beta
-
Von Hoegen, P.; Zawatzky, R.; Schirrmacher, V. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-α/beta. Cell. Immunol. 1990, 126, 80-90.
-
(1990)
Cell. Immunol.
, vol.126
, pp. 80-90
-
-
Von Hoegen, P.1
Zawatzky, R.2
Schirrmacher, V.3
-
52
-
-
85058306194
-
Antitumor immune memory and its activation for control of residual tumor cells and improvement of patient survival
-
In, Sinkovics, J., Horvath, J., Eds.; Marcel Decker: New York, NY, USA
-
Schirrmacher, V. Antitumor immune memory and its activation for control of residual tumor cells and improvement of patient survival. In Virus Therapy of Human Cancers; Sinkovics, J., Horvath, J., Eds.; Marcel Decker: New York, NY, USA, 2004; pp. 481-531.
-
(2004)
Virus Therapy of Human Cancers
, pp. 481-531
-
-
Schirrmacher, V.1
-
53
-
-
77954238185
-
Role of type 1 IFNs in antiglioma immunosurveillance-Using mouse studies to guide examination of novel prognostic markers in humans
-
Fujita, M.; Scheurer, M.E.; Decker, S.A.; McDonald, H.A.; Kohanbash, G.; Kastenhuber, E.R.; Kato, H.; Bondy, M.L.; Ohlfest, J.R.; Okada, H. Role of type 1 IFNs in antiglioma immunosurveillance-Using mouse studies to guide examination of novel prognostic markers in humans. Clin. Cancer Res. 2010, 16, 3409-3421.
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 3409-3421
-
-
Fujita, M.1
Scheurer, M.E.2
Decker, S.A.3
McDonald, H.A.4
Kohanbash, G.5
Kastenhuber, E.R.6
Kato, H.7
Bondy, M.L.8
Ohlfest, J.R.9
Okada, H.10
-
54
-
-
0034037655
-
Newcastle-Disease-Virus infection induces a B7-1/B7-2 independent T cell-co-stimulatory activity in human melanoma cells
-
Termeer, C.C.; Schirrmacher, V.; Bröcker, E.B.; Becker, J.C. Newcastle-Disease-Virus infection induces a B7-1/B7-2 independent T cell-co-stimulatory activity in human melanoma cells. Cancer Gene Ther. 2000, 7, 316-323.
-
(2000)
Cancer Gene Ther.
, vol.7
, pp. 316-323
-
-
Termeer, C.C.1
Schirrmacher, V.2
Bröcker, E.B.3
Becker, J.C.4
-
55
-
-
0033795196
-
Interferons: Cell signalling, immune modulation, anti-viral response and virus countermeasures
-
Goodbourn, L.D.; Randall, R.E. Interferons: Cell signalling, immune modulation, anti-viral response and virus countermeasures. J. Gen. Virol. 2000, 81, 2341-2364.
-
(2000)
J. Gen. Virol.
, vol.81
, pp. 2341-2364
-
-
Goodbourn, L.D.1
Randall, R.E.2
-
56
-
-
0016382090
-
Viruses as immunological adjuvants in cancer
-
Lindenmann, J. Viruses as immunological adjuvants in cancer. Biochim. Biophys. Acta. 1974, 355, 49-75.
-
(1974)
Biochim. Biophys. Acta
, vol.355
, pp. 49-75
-
-
Lindenmann, J.1
-
57
-
-
0027723261
-
New developments in the virus therapy of cancer: A historical review
-
Sinkovics, J.; Horvath, J. New developments in the virus therapy of cancer: A historical review. Intervirology 1993, 36, 193-214.
-
(1993)
Intervirology
, vol.36
, pp. 193-214
-
-
Sinkovics, J.1
Horvath, J.2
-
58
-
-
33645438927
-
Oncolytic effect of Newcastle disease virus on Yoshida sarcoma (1)
-
Goto, M.; Okazaki, M.; Yazaki, H. Oncolytic effect of Newcastle disease virus on Yoshida sarcoma (1). Jpn. J. Microbiol. 1959, 3, 171-181.
-
(1959)
Jpn. J. Microbiol.
, vol.3
, pp. 171-181
-
-
Goto, M.1
Okazaki, M.2
Yazaki, H.3
-
59
-
-
0142175171
-
Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report
-
Wheelock, E.F.; Dingle, J.H. Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report. N. Engl. J. Med. 1964, 271, 645-651.
-
(1964)
N. Engl. J. Med.
, vol.271
, pp. 645-651
-
-
Wheelock, E.F.1
Dingle, J.H.2
-
60
-
-
78651190570
-
Newcastle Disease Virus as an antineoplastic agent
-
Cassel, W.A.; Garrett, R.E. Newcastle Disease Virus as an antineoplastic agent. Cancer 1965, 1, 863-888.
-
(1965)
Cancer
, vol.1
, pp. 863-888
-
-
Cassel, W.A.1
Garrett, R.E.2
-
61
-
-
0014220521
-
Oncolytic power in vivo of the Newcastle virus with regard to sarcoma ascitic Yoshida
-
Jacotot, H. Oncolytic power in vivo of the Newcastle virus with regard to sarcoma ascitic Yoshida. C. R. Acad. Sci. Hebd. Seances Acad. Sci. D 1967, 26422, 2602-2603.
-
(1967)
C. R. Acad. Sci. Hebd. Seances Acad. Sci. D
, pp. 2602-2603
-
-
Jacotot, H.1
-
62
-
-
0015216752
-
Viruses in the treatment of cancer
-
Csatary, L.K. Viruses in the treatment of cancer. Lancet 1971, 2, 825.
-
(1971)
Lancet
, vol.2
, pp. 825
-
-
Csatary, L.K.1
-
63
-
-
0032921653
-
Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H)
-
Csatary, L.K.; Moss, R.W.; Beuth, J.; Torocsik, B.; Szeberenyi, J.; Bakacs, T. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res. 1999, 19, 635-638.
-
(1999)
Anticancer Res.
, vol.19
, pp. 635-638
-
-
Csatary, L.K.1
Moss, R.W.2
Beuth, J.3
Torocsik, B.4
Szeberenyi, J.5
Bakacs, T.6
-
64
-
-
0027144317
-
Attenuated veterinary virus vaccine for the treatment of cancer
-
Csatary, L.K.; Eckhardt, S.; Bukosza, I.; Czegledi, F.; Fenyvesi, C.; Gergely, P.; Bodey, B.; Csatary, C.M. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect. Prev. 1993, 17, 619-627.
-
(1993)
Cancer Detect. Prev.
, vol.17
, pp. 619-627
-
-
Csatary, L.K.1
Eckhardt, S.2
Bukosza, I.3
Czegledi, F.4
Fenyvesi, C.5
Gergely, P.6
Bodey, B.7
Csatary, C.M.8
-
65
-
-
0033526315
-
Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma
-
Csatary, L.K.; Bakacs, T. Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 1999, 281, 1588-1589.
-
(1999)
JAMA
, vol.281
, pp. 1588-1589
-
-
Csatary, L.K.1
Bakacs, T.2
-
66
-
-
0037897450
-
On the origins and relationships of Newcastle disease virus vaccine strains Hertfordshire and Mukteswa and virulent strain Herts'33
-
Czegledi, A.; Wehmann, E.; Lomniczi, B. On the origins and relationships of Newcastle disease virus vaccine strains Hertfordshire and Mukteswa and virulent strain Herts'33. Avian Pathol. 2003, 32, 271-276.
-
(2003)
Avian Pathol.
, vol.32
, pp. 271-276
-
-
Czegledi, A.1
Wehmann, E.2
Lomniczi, B.3
-
67
-
-
0347364683
-
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
-
Nefedova, Y.; Huang, M.; Kusmartsev, S.; Bhattacharya, R.; Cheng, P.; Salup, R.; Jove, R.; Gabrilovich, D. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 2004, 172, 464-474.
-
(2004)
J. Immunol.
, vol.172
, pp. 464-474
-
-
Nefedova, Y.1
Huang, M.2
Kusmartsev, S.3
Bhattacharya, R.4
Cheng, P.5
Salup, R.6
Jove, R.7
Gabrilovich, D.8
-
68
-
-
0033589208
-
Scientific interest in newcastle disease virus is reviving
-
Nelson, J. Scientific interest in newcastle disease virus is reviving. J. Natl. Cancer Inst. 1999, 91, 1708-1710.
-
(1999)
J. Natl. Cancer Inst.
, vol.91
, pp. 1708-1710
-
-
Nelson, J.1
-
69
-
-
0028081158
-
Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy
-
Lorence, R.M.; Katubig, B.B.; Reichard, K.W.; Reyes, H.M.; Phuangsab, A.; Sassetti, M.D.; Walter, R.J.; Peeples, M.E. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 1994, 54, 6017-6021.
-
(1994)
Cancer Res.
, vol.54
, pp. 6017-6021
-
-
Lorence, R.M.1
Katubig, B.B.2
Reichard, K.W.3
Reyes, H.M.4
Phuangsab, A.5
Sassetti, M.D.6
Walter, R.J.7
Peeples, M.E.8
-
70
-
-
0027980233
-
Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy
-
Lorence, R.M.; Reichard, K.W.; Katubig, B.B.; Reyes, H.M.; Phuangsab, A.; Mitchell, B.R.; Cascino, C.J.; Walter, R.J.; Peeples, M.E. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J. Natl. Cancer Inst. 1994, 86, 1228-1233.
-
(1994)
J. Natl. Cancer Inst.
, vol.86
, pp. 1228-1233
-
-
Lorence, R.M.1
Reichard, K.W.2
Katubig, B.B.3
Reyes, H.M.4
Phuangsab, A.5
Mitchell, B.R.6
Cascino, C.J.7
Walter, R.J.8
Peeples, M.E.9
-
71
-
-
33847378044
-
Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus
-
Lorence, R.M.; Roberts, M.S.; O'Neil, J.D.; Groene, W.S.; Miller, J.A.; Mueller, S.N.; Bamat, M.K. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr. Cancer Drug Targets 2007, 7, 157-167.
-
(2007)
Curr. Cancer Drug Targets
, vol.7
, pp. 157-167
-
-
Lorence, R.M.1
Roberts, M.S.2
O'Neil, J.D.3
Groene, W.S.4
Miller, J.A.5
Mueller, S.N.6
Bamat, M.K.7
-
72
-
-
0036569510
-
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers
-
Pecora, A.L.; Rizvi, N.; Cohen, G.I.; Meropol, N.J.; Sterman, D.; Marshall, J.L.; Goldberg, S.; Gross, P.; O'Neil, J.D.; Groene, W.S.; et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 2002, 20, 2251-2266.
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 2251-2266
-
-
Pecora, A.L.1
Rizvi, N.2
Cohen, G.I.3
Meropol, N.J.4
Sterman, D.5
Marshall, J.L.6
Goldberg, S.7
Gross, P.8
O'Neil, J.D.9
Groene, W.S.10
-
73
-
-
33646389525
-
A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization
-
Laurie, S.A.; Bell, J.C.; Atkins, H.L.; Roach, J.; Bamat, M.K.; O'Neil, J.D.; Roberts, M.S.; Groene, W.S.; Lorence, R.M. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin. Cancer Res. 2006, 12, 2555-2562.
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 2555-2562
-
-
Laurie, S.A.1
Bell, J.C.2
Atkins, H.L.3
Roach, J.4
Bamat, M.K.5
O'Neil, J.D.6
Roberts, M.S.7
Groene, W.S.8
Lorence, R.M.9
-
74
-
-
33847417019
-
An optimized clinical regimen for the oncolytic virus PV701
-
Hotte, S.J.; Lorence, R.M.; Hirte, H.W.; Polawski, S.R.; Bamat, M.K.; O'Neil, J.D.; Roberts, M.S.; Groene, W.S.; Major, P.P. An optimized clinical regimen for the oncolytic virus PV701. Clin. Cancer Res. 2007, 13, 977-985.
-
(2007)
Clin. Cancer Res.
, vol.13
, pp. 977-985
-
-
Hotte, S.J.1
Lorence, R.M.2
Hirte, H.W.3
Polawski, S.R.4
Bamat, M.K.5
O'Neil, J.D.6
Roberts, M.S.7
Groene, W.S.8
Major, P.P.9
-
75
-
-
0346458886
-
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus
-
Lorence, R.M.; Pecora, A.L.; Major, P.P.; Hotte, S.J.; Laurie, S.A.; Roberts, M.S.; Groene, W.S.; Bamat, M.K. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr. Opin. Mol. Ther. 2003, 5, 618-624.
-
(2003)
Curr. Opin. Mol. Ther.
, vol.5
, pp. 618-624
-
-
Lorence, R.M.1
Pecora, A.L.2
Major, P.P.3
Hotte, S.J.4
Laurie, S.A.5
Roberts, M.S.6
Groene, W.S.7
Bamat, M.K.8
-
76
-
-
0035935255
-
Newcastle disease virus therapy of human tumor xenografts: Anti-tumor effects of local or systemic administration
-
Phuangsab, A.; Lorence, M.; Reichard, K.W.; Peeples, M.E.; Walter, R.J. Newcastle disease virus therapy of human tumor xenografts: Anti-tumor effects of local or systemic administration. Cancer Lett. 2001, 172, 27-36.
-
(2001)
Cancer Lett.
, vol.172
, pp. 27-36
-
-
Phuangsab, A.1
Lorence, M.2
Reichard, K.W.3
Peeples, M.E.4
Walter, R.J.5
-
77
-
-
1842484851
-
MTH-68/H oncolytic viral treatment in human high-grade gliomas
-
Csatary, L.K.; Gosztonyi, G.; Szeberenyi, J.; Fabian, Z.; Liszka, V.; Bodey, B.; Csatary, C.M. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J. Neurooncol. 2004, 67, 83-93.
-
(2004)
J. Neurooncol.
, vol.67
, pp. 83-93
-
-
Csatary, L.K.1
Gosztonyi, G.2
Szeberenyi, J.3
Fabian, Z.4
Liszka, V.5
Bodey, B.6
Csatary, C.M.7
-
78
-
-
28844468988
-
Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme
-
Freeman, A.I.; Zakay-Rones, Z.; Gomori, J.M.; Linetsky, E.; Rasooly, L.; Greenbaum, E.; Rozenman-Yair, S.; Panet, A.; Libson, E.; Irving, C.S.; et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 2006, 13, 221-228.
-
(2006)
Mol. Ther.
, vol.13
, pp. 221-228
-
-
Freeman, A.I.1
Zakay-Rones, Z.2
Gomori, J.M.3
Linetsky, E.4
Rasooly, L.5
Greenbaum, E.6
Rozenman-Yair, S.7
Panet, A.8
Libson, E.9
Irving, C.S.10
-
79
-
-
0018737217
-
Virus augmentation of the antigenicity of tumor cell extracts
-
Austin, F.C.; Boone, C.W. Virus augmentation of the antigenicity of tumor cell extracts. Adv. Cancer Res. 1979, 30, 301-345.
-
(1979)
Adv. Cancer Res.
, vol.30
, pp. 301-345
-
-
Austin, F.C.1
Boone, C.W.2
-
81
-
-
0017718208
-
Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses
-
Cassel, W.A.; Murray, D.R.; Torbin, A.H.; Olkowski, Z.L.; Moore, M.E. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses. Cancer 1977, 40, 672-679.
-
(1977)
Cancer
, vol.40
, pp. 672-679
-
-
Cassel, W.A.1
Murray, D.R.2
Torbin, A.H.3
Olkowski, Z.L.4
Moore, M.E.5
-
82
-
-
0017663606
-
Viral oncolysate in the management of malignant melanoma. II. Clinical studies
-
Murray, D.R.; Cassel, W.A.; Torbin, A.H.; Olkowski, Z.L.; Moore, M.E. Viral oncolysate in the management of malignant melanoma. II. Clinical studies. Cancer 1977, 40, 680-686.
-
(1977)
Cancer
, vol.40
, pp. 680-686
-
-
Murray, D.R.1
Cassel, W.A.2
Torbin, A.H.3
Olkowski, Z.L.4
Moore, M.E.5
-
83
-
-
0027059174
-
A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate
-
Cassel, W.A.; Murray, D.R. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med. Oncol. Tumor Pharmacother. 1992, 9, 169-171.
-
(1992)
Med. Oncol. Tumor Pharmacother.
, vol.9
, pp. 169-171
-
-
Cassel, W.A.1
Murray, D.R.2
-
84
-
-
33645350675
-
Newcastle disease virus: Its oncolytic properties oncolysate
-
In, Sinkovics, J.G., Horvath, J.C., Eds.; Marcel Dekker: New York, NY, USA
-
Horvath, J.C. Newcastle disease virus: Its oncolytic properties oncolysate. In Viral Therapy of Human Cancers; Sinkovics, J.G., Horvath, J.C., Eds.; Marcel Dekker: New York, NY, USA, 2005; pp. 533-574.
-
(2005)
Viral Therapy of Human Cancers
, pp. 533-574
-
-
Horvath, J.C.1
-
85
-
-
18144363557
-
Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory
-
Schirrmacher, V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory. Cancer Immunol. Immunother. 2005, 54, 587-598.
-
(2005)
Cancer Immunol. Immunother.
, vol.54
, pp. 587-598
-
-
Schirrmacher, V.1
-
86
-
-
0022964916
-
Successful application of non-oncogenic viruses for antimetastatic cancer immunotherapy
-
Schirrmacher, V.; Ahlert, T.; Heicappell, R.; Appelhans, B.; von Hoegen, P. Successful application of non-oncogenic viruses for antimetastatic cancer immunotherapy. Cancer Rev. 1986, 5, 19-49.
-
(1986)
Cancer Rev.
, vol.5
, pp. 19-49
-
-
Schirrmacher, V.1
Ahlert, T.2
Heicappell, R.3
Appelhans, B.4
von Hoegen, P.5
-
87
-
-
0022611296
-
Prevention of metastatic spread by post-operative immunotherapy with virally modified autologous tumor cells. I: Parameters for optimal therapeutic effects
-
Heicappell, R.; Schirrmacher, V.; von Hoegen, P.; Ahlert, T.; Appelhans, B. Prevention of metastatic spread by post-operative immunotherapy with virally modified autologous tumor cells. I: Parameters for optimal therapeutic effects. Int. J. Cancer 1986, 37, 569-577.
-
(1986)
Int. J. Cancer
, vol.37
, pp. 569-577
-
-
Heicappell, R.1
Schirrmacher, V.2
von Hoegen, P.3
Ahlert, T.4
Appelhans, B.5
-
88
-
-
58149379647
-
Newcastle Disease Virus: A Promising Vector for Viral Therapy of Cancer
-
doi:10.1002/9780470985793.ch10
-
Schirrmacher, V.; Fournier, P. Newcastle Disease Virus: A Promising Vector for Viral Therapy of Cancer. Viral Ther. Cancer. 2009, doi:10.1002/9780470985793.ch10.
-
(2009)
Viral Ther. Cancer
-
-
Schirrmacher, V.1
Fournier, P.2
-
89
-
-
0030951625
-
Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
-
Ahlert, T.; Sauerbrei, W.; Bastert, G.; Ruhland, S.; Bartik, B.; Simiantonaki, N.; Schumacher, J.; Häcker, B.; Schumacher, M.; Schirrmacher, V. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J. Clin. Oncol. 1997, 15, 1354-1366.
-
(1997)
J. Clin. Oncol.
, vol.15
, pp. 1354-1366
-
-
Ahlert, T.1
Sauerbrei, W.2
Bastert, G.3
Ruhland, S.4
Bartik, B.5
Simiantonaki, N.6
Schumacher, J.7
Häcker, B.8
Schumacher, M.9
Schirrmacher, V.10
-
90
-
-
8944263472
-
Newcastle Disease Virus infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma
-
Ockert, D.; Schirrmacher, V.; Beck, N.; Stoelben, E.; Ahlert, T.; Flechtenmacher, J.; Hagmüller, E.; Buchcik, R.; Nagel, M.; Saeger, H.D. Newcastle Disease Virus infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin. Cancer Res. 1996, 2, 21-28.
-
(1996)
Clin. Cancer Res.
, vol.2
, pp. 21-28
-
-
Ockert, D.1
Schirrmacher, V.2
Beck, N.3
Stoelben, E.4
Ahlert, T.5
Flechtenmacher, J.6
Hagmüller, E.7
Buchcik, R.8
Nagel, M.9
Saeger, H.D.10
-
91
-
-
0026744022
-
Active specific Immunotherapy with NDV modified autologous tumor cells following liver metastases resection in colorectal cancer: First evaluation of clinical response of a Phase II trial
-
Schlag, P.; Manasterski, M.; Gerneth, T.; Hohenberger, P.; Dueck, M.; Herfarth, C.; Liebrich, W.; Schirrmacher, V. Active specific Immunotherapy with NDV modified autologous tumor cells following liver metastases resection in colorectal cancer: First evaluation of clinical response of a Phase II trial. Cancer Immunol. Immunother. 1992, 35, 325-330.
-
(1992)
Cancer Immunol. Immunother.
, vol.35
, pp. 325-330
-
-
Schlag, P.1
Manasterski, M.2
Gerneth, T.3
Hohenberger, P.4
Dueck, M.5
Herfarth, C.6
Liebrich, W.7
Schirrmacher, V.8
-
92
-
-
16544392098
-
Anti-tumor vaccination of patients with glioblastoma multiforme: A pilot study to assess: Feasibility, safety and clinical benefit
-
Steiner, H.H.; Bonsanto, M.M.; Beckhove, P.; Brysch, M.; Geletneky, K.; Ahmadi, R.; Schuele-Freyer, R.; Kremer, P.; Ranaie, G.; Matejic, D.; et al. Anti-tumor vaccination of patients with glioblastoma multiforme: A pilot study to assess: Feasibility, safety and clinical benefit. J. Clin. Oncol. 2004, 22, 4272-4281.
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 4272-4281
-
-
Steiner, H.H.1
Bonsanto, M.M.2
Beckhove, P.3
Brysch, M.4
Geletneky, K.5
Ahmadi, R.6
Schuele-Freyer, R.7
Kremer, P.8
Ranaie, G.9
Matejic, D.10
-
93
-
-
7444229927
-
Anti-tumor vaccination with HNSCC with autologous virus-modified tumor cells
-
Karcher, J.; Dyckhoff, G.; Beckhove, P.; Reisser, C.; Brysch, M.; Ziouta, Y.; Helmke, B.H.; Weidauer, H.; Schirrmacher, V.; Herold-Mende, C. Anti-tumor vaccination with HNSCC with autologous virus-modified tumor cells. Cancer Res. 2004, 64, 8057-8061.
-
(2004)
Cancer Res.
, vol.64
, pp. 8057-8061
-
-
Karcher, J.1
Dyckhoff, G.2
Beckhove, P.3
Reisser, C.4
Brysch, M.5
Ziouta, Y.6
Helmke, B.H.7
Weidauer, H.8
Schirrmacher, V.9
Herold-Mende, C.10
-
94
-
-
54849420913
-
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: Results of a prospective randomized trial
-
Schulze, T.; Kemmner, W.; Weitz, J.; Wernecke, K.D.; Schirrmacher, V.; Schlag, P.M. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: Results of a prospective randomized trial. Cancer Immunol. Immunother. 2009, 58, 61-69.
-
(2009)
Cancer Immunol. Immunother.
, vol.58
, pp. 61-69
-
-
Schulze, T.1
Kemmner, W.2
Weitz, J.3
Wernecke, K.D.4
Schirrmacher, V.5
Schlag, P.M.6
-
95
-
-
0015619335
-
Identification of a novel cell type 1 peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution
-
Steinman, R.M.; Cohn, Z.A. Identification of a novel cell type 1 peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 1973, 137, 1142-1162.
-
(1973)
J. Exp. Med.
, vol.137
, pp. 1142-1162
-
-
Steinman, R.M.1
Cohn, Z.A.2
-
96
-
-
83455224662
-
The 2011 Nobel Prize in physiology or medicine
-
Volchenkov, R.; Sprater, F.; Vogelsang, P.; Appel, S. The 2011 Nobel Prize in physiology or medicine. Scand. J. Immunol. 2012, 75, 1-4.
-
(2012)
Scand. J. Immunol.
, vol.75
, pp. 1-4
-
-
Volchenkov, R.1
Sprater, F.2
Vogelsang, P.3
Appel, S.4
-
97
-
-
0028096181
-
Development of the airway intraepithelial dendritic cell network in the rat from class-II major histocompatibility (Ia)-negative precursors: Differential regulation of Ia expression at different levels of the respiratory tract
-
Nelson, D.J.; McMenamin, C.; McWilliam, A.S.; Brenan, M.; Holt, P.G. Development of the airway intraepithelial dendritic cell network in the rat from class-II major histocompatibility (Ia)-negative precursors: Differential regulation of Ia expression at different levels of the respiratory tract. J. Exp. Med. 1994, 179, 203-212.
-
(1994)
J. Exp. Med.
, vol.179
, pp. 203-212
-
-
Nelson, D.J.1
McMenamin, C.2
McWilliam, A.S.3
Brenan, M.4
Holt, P.G.5
-
98
-
-
0012929728
-
Toll-like receptors
-
Takeda, K.; Kaisho, T.; Akira, S. Toll-like receptors. Annu. Rev. Immunol. 2003, 21, 335-376.
-
(2003)
Annu. Rev. Immunol.
, vol.21
, pp. 335-376
-
-
Takeda, K.1
Kaisho, T.2
Akira, S.3
-
99
-
-
34548418935
-
Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response
-
Thompson, A.J.; Locarnini, S.A. Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Immunol. Cell. Biol. 2007, 85, 435-445.
-
(2007)
Immunol. Cell. Biol.
, vol.85
, pp. 435-445
-
-
Thompson, A.J.1
Locarnini, S.A.2
-
100
-
-
0030586611
-
Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion
-
Finkelman, F.D.; Lees, A.; Birnbaum, R.; Gause, W.C.; Morris, S.C. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J. Immunol. 1996, 157, 1406-1414.
-
(1996)
J. Immunol.
, vol.157
, pp. 1406-1414
-
-
Finkelman, F.D.1
Lees, A.2
Birnbaum, R.3
Gause, W.C.4
Morris, S.C.5
-
101
-
-
0017126775
-
Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay
-
Bevan, M.J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 1976, 143, 1283-1288.
-
(1976)
J. Exp. Med.
, vol.143
, pp. 1283-1288
-
-
Bevan, M.J.1
-
102
-
-
3543053363
-
Immature dendritic cells phagocytose apoptotic cells via αvbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
-
Albert, M.L.; Pearce, S.F.; Francisco, L.M.; Sauter, B.; Roy, P.; Silverstein, R.L.; Bhardwaj, N. Immature dendritic cells phagocytose apoptotic cells via αvbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 1998, 188, 1359-1368.
-
(1998)
J. Exp. Med.
, vol.188
, pp. 1359-1368
-
-
Albert, M.L.1
Pearce, S.F.2
Francisco, L.M.3
Sauter, B.4
Roy, P.5
Silverstein, R.L.6
Bhardwaj, N.7
-
103
-
-
32644461186
-
Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction
-
Yamazaki, S.; Patel, M.; Harper, A.; Bonito, A.; Fukuyama, H.; Pack, M.; Tarbell, K.V.; Talmor, M.; Ravetch, J.V.; Inaba, K.; et al. Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc. Natl. Acad. Sci. USA 2006, 103, 2758-2763.
-
(2006)
Proc. Natl. Acad. Sci. USA
, vol.103
, pp. 2758-2763
-
-
Yamazaki, S.1
Patel, M.2
Harper, A.3
Bonito, A.4
Fukuyama, H.5
Pack, M.6
Tarbell, K.V.7
Talmor, M.8
Ravetch, J.V.9
Inaba, K.10
-
104
-
-
0026791975
-
The immune system evolved to discriminate infectious nonself from non-infectious self
-
Janeway, C.A., Jr. The immune system evolved to discriminate infectious nonself from non-infectious self. Immunol. Today 1992, 13, 11-16.
-
(1992)
Immunol. Today
, vol.13
, pp. 11-16
-
-
Janeway Jr., C.A.1
-
105
-
-
0028201732
-
Tolerance, danger and the extended family
-
Matzinger, P. Tolerance, danger and the extended family. Annu. Rev. Immunol. 1994, 12, 991-1045.
-
(1994)
Annu. Rev. Immunol.
, vol.12
, pp. 991-1045
-
-
Matzinger, P.1
-
106
-
-
67650650986
-
Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4
-
Kalinski, P. Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. Curr. Opin. Invest. Drugs. 2009, 10, 526-535.
-
(2009)
Curr. Opin. Invest. Drugs.
, vol.10
, pp. 526-535
-
-
Kalinski, P.1
-
107
-
-
0037544148
-
Signal 3 determines tolerance versus full activation of naive CD8 T cells: Dissociating proliferation and development of effector function
-
Curtsinger, J.M.; Lins, D.C.; Mescher, M.F. Signal 3 determines tolerance versus full activation of naive CD8 T cells: Dissociating proliferation and development of effector function. J. Exp. Med. 2003, 197, 1141-1151.
-
(2003)
J. Exp. Med.
, vol.197
, pp. 1141-1151
-
-
Curtsinger, J.M.1
Lins, D.C.2
Mescher, M.F.3
-
108
-
-
0242579946
-
CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine
-
Curtsinger, J.M.; Johnson, C.M.; Mescher, M.F. CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J. Immunol. 2003, 171, 5165-5171.
-
(2003)
J. Immunol.
, vol.171
, pp. 5165-5171
-
-
Curtsinger, J.M.1
Johnson, C.M.2
Mescher, M.F.3
-
109
-
-
77953541634
-
Inflammatory cytokines as a third signal for T cell activation
-
Curtsinger, J.M.; Mescher, M.F. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 2010, 22, 333-340.
-
(2010)
Curr. Opin. Immunol.
, vol.22
, pp. 333-340
-
-
Curtsinger, J.M.1
Mescher, M.F.2
-
110
-
-
33746013487
-
Inflaming the CD8+ T cell response
-
Haring, J.S.; Badovinac, V.P.; Harty, J.T. Inflaming the CD8+ T cell response. Immunity 2006, 25, 19-29.
-
(2006)
Immunity
, vol.25
, pp. 19-29
-
-
Haring, J.S.1
Badovinac, V.P.2
Harty, J.T.3
-
111
-
-
31144469922
-
Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines
-
Dolan, B.P.; Gibbs, K.D., Jr.; Ostrand-Rosenberg, S. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J. Immunol. 2006, 176, 1447-1455.
-
(2006)
J. Immunol
, vol.176
, pp. 1447-1455
-
-
Dolan, B.P.1
Gibbs Jr., K.D.2
Ostrand-Rosenberg, S.3
-
112
-
-
79953238006
-
Cross-dressed dendritic cells drive memory CD8+ T cell activation after viral infection
-
Wakim, L.M.; Bevan, M.J. Cross-dressed dendritic cells drive memory CD8+ T cell activation after viral infection. Nature 2011, 471, 629-632.
-
(2011)
Nature
, vol.471
, pp. 629-632
-
-
Wakim, L.M.1
Bevan, M.J.2
-
113
-
-
33750341482
-
Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells
-
Dolan, B.P.; Gibbs, K.D., Jr.; Ostrand-Rosenberg, S. Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. J. Immunol. 2006, 177, 6018-6024.
-
(2006)
J. Immunol.
, vol.177
, pp. 6018-6024
-
-
Dolan, B.P.1
Gibbs Jr., K.D.2
Ostrand-Rosenberg, S.3
-
114
-
-
0037443473
-
Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo
-
Kleindienst, P.; Brocker, T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J. Immunol. 2003, 170, 2817-2823.
-
(2003)
J. Immunol.
, vol.170
, pp. 2817-2823
-
-
Kleindienst, P.1
Brocker, T.2
-
115
-
-
79953313061
-
Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines
-
Petersen, T.R.; Sika-Paotonu, D.; Knight, D.A.; Simkins, H.M.A.; Hermans, I.F. Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines. PLoS One 2011, 6, e17657.
-
(2011)
PLoS One
, vol.6
-
-
Petersen, T.R.1
Sika-Paotonu, D.2
Knight, D.A.3
Simkins, H.M.A.4
Hermans, I.F.5
-
116
-
-
0036083905
-
Exploiting dendritic cells to improve vaccine efficacy
-
Steinman, R.M.; Pope, M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 2002, 109, 1519-1526.
-
(2002)
J. Clin. Invest
, vol.109
, pp. 1519-1526
-
-
Steinman, R.M.1
Pope, M.2
-
117
-
-
0025004169
-
Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ
-
Inaba, K.; Metlay, J.P.; Crowley, M.T.; Steinman, R.M. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med. 1990, 172, 631-640.
-
(1990)
J. Exp. Med.
, vol.172
, pp. 631-640
-
-
Inaba, K.1
Metlay, J.P.2
Crowley, M.T.3
Steinman, R.M.4
-
118
-
-
0026481133
-
Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
-
Inaba, K.; Inaba, M.; Romani, N.; Aya, H.; Deguchi, M.; Ikehara, S.; Muramatsu, S.; Steinman, R.M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1992, 176, 1693-1702.
-
(1992)
J. Exp. Med.
, vol.176
, pp. 1693-1702
-
-
Inaba, K.1
Inaba, M.2
Romani, N.3
Aya, H.4
Deguchi, M.5
Ikehara, S.6
Muramatsu, S.7
Steinman, R.M.8
-
119
-
-
0030026776
-
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
-
Hsu, F.J.; Benike, C.; Fagnoni, F.; Liles, T.M.; Czerwinski, D.; Taidi, B.; Engleman, E.G.; Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 1996, 2, 52-58.
-
(1996)
Nat. Med.
, vol.2
, pp. 52-58
-
-
Hsu, F.J.1
Benike, C.2
Fagnoni, F.3
Liles, T.M.4
Czerwinski, D.5
Taidi, B.6
Engleman, E.G.7
Levy, R.8
-
120
-
-
0031941423
-
Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells
-
Nestle, F.O.; Alijagic, S.; Gilliet, M.; Sun, Y.; Grabbe, S.; Dummer, R.; Burg, G.; Schadendorf, D. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 1998, 4, 328-332.
-
(1998)
Nat. Med.
, vol.4
, pp. 328-332
-
-
Nestle, F.O.1
Alijagic, S.2
Gilliet, M.3
Sun, Y.4
Grabbe, S.5
Dummer, R.6
Burg, G.7
Schadendorf, D.8
-
121
-
-
33746012881
-
Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC-8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
-
Small, E.J.; Schellhammer, P.F.; Higano, C.S.; Redfern, C.H.; Nemunaitis, J.J.; Valone, F.H.; Verjee, S.S.; Jones, L.A.; Hershberg, R.M. Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC-8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 2006, 24, 3089-3094.
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 3089-3094
-
-
Small, E.J.1
Schellhammer, P.F.2
Higano, C.S.3
Redfern, C.H.4
Nemunaitis, J.J.5
Valone, F.H.6
Verjee, S.S.7
Jones, L.A.8
Hershberg, R.M.9
-
122
-
-
38949139497
-
Combined clinical trial results of a HER2/neu (E-75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
-
Peoples, G.E.; Holmes, J.P.; Hueman, M.T.; Mittendorf, E.A.; Amin, A.; Khoo, S.; Dehqanzada, Z.A.; Gurney, J.M.; Woll, M.M.; Ryan, G.B.; et al. Combined clinical trial results of a HER2/neu (E-75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 2008, 14, 797-803.
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 797-803
-
-
Peoples, G.E.1
Holmes, J.P.2
Hueman, M.T.3
Mittendorf, E.A.4
Amin, A.5
Khoo, S.6
Dehqanzada, Z.A.7
Gurney, J.M.8
Woll, M.M.9
Ryan, G.B.10
-
123
-
-
0032546352
-
Dendritic cells and the control of immunity
-
Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 392, 245-252.
-
(1998)
Nature
, vol.392
, pp. 245-252
-
-
Banchereau, J.1
Steinman, R.M.2
-
124
-
-
34848837386
-
Taking dendritic cells into medicine
-
Steinman, R.M.; Banchereau, J. Taking dendritic cells into medicine. Nature 2007, 449, 419-426.
-
(2007)
Nature
, vol.449
, pp. 419-426
-
-
Steinman, R.M.1
Banchereau, J.2
-
125
-
-
34748886192
-
Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting
-
Tacken, P.J.; de Vries, I.J.; Torensma, R.; Figdor, C.G. Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 2007, 7, 790-802.
-
(2007)
Nat. Rev. Immunol.
, vol.7
, pp. 790-802
-
-
Tacken, P.J.1
de Vries, I.J.2
Torensma, R.3
Figdor, C.G.4
-
126
-
-
0035892109
-
Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10
-
Brown, R.D.; Pope, B.; Murray, A.; Esdale, W.; Sze, D.M.; Gibson, J.; Ho, P.J.; Hart, D.; Joshua, D. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10. Blood 2001, 98, 2992-2998.
-
(2001)
Blood
, vol.98
, pp. 2992-2998
-
-
Brown, R.D.1
Pope, B.2
Murray, A.3
Esdale, W.4
Sze, D.M.5
Gibson, J.6
Ho, P.J.7
Hart, D.8
Joshua, D.9
-
127
-
-
0036659945
-
Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6
-
Ratta, M.; Fagnoni, F.; Curti, A.; Vescovini, R.; Sansoni, P.; Oliviero, B.; Fogli, M.; Ferri, E.; Della Cuna, G.R.; Tura, S.; et al. Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood 2002, 100, 230-237.
-
(2002)
Blood
, vol.100
, pp. 230-237
-
-
Ratta, M.1
Fagnoni, F.2
Curti, A.3
Vescovini, R.4
Sansoni, P.5
Oliviero, B.6
Fogli, M.7
Ferri, E.8
Della Cuna, G.R.9
Tura, S.10
-
128
-
-
79960880111
-
Dendritic cells and malignant plasma cells: An alliance in multiple myeloma tumor progression?
-
Tucci, M.; Stucci, S.; Strippoli, S.; Dammacco, F.; Silvestris, F. Dendritic cells and malignant plasma cells: An alliance in multiple myeloma tumor progression? Oncologist 2011, 16, 1040-1048.
-
(2011)
Oncologist
, vol.16
, pp. 1040-1048
-
-
Tucci, M.1
Stucci, S.2
Strippoli, S.3
Dammacco, F.4
Silvestris, F.5
-
129
-
-
33646575622
-
In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma
-
Beyer, M.; Kochanek, M.; Giese, T.; Endl, E.; Weihrauch, M.R.; Knolle, P.A.; Classen, S.; Schultze, J.L. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006, 107, 3940-3949.
-
(2006)
Blood
, vol.107
, pp. 3940-3949
-
-
Beyer, M.1
Kochanek, M.2
Giese, T.3
Endl, E.4
Weihrauch, M.R.5
Knolle, P.A.6
Classen, S.7
Schultze, J.L.8
-
130
-
-
65249138393
-
Myeloid-derived suppressor cells: Linking inflammation and cancer
-
Ostrand-Rosenberg, S.; Sinha, P. Myeloid-derived suppressor cells: Linking inflammation and cancer. J. Immunol. 2009, 182, 4499-4506.
-
(2009)
J. Immunol.
, vol.182
, pp. 4499-4506
-
-
Ostrand-Rosenberg, S.1
Sinha, P.2
-
131
-
-
0037226599
-
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state
-
De Vries, I.J.; Krooshoop, D.J.; Scharenborg, N.M.; Lesterhuis, W.J.; Diepstra, J.H.; van Muijen, G.N.; Strijk, S.P.; Ruers, T.J.; Boerman, O.C.; Oyen, W.J.; et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003, 63, 12-17.
-
(2003)
Cancer Res.
, vol.63
, pp. 12-17
-
-
De Vries, I.J.1
Krooshoop, D.J.2
Scharenborg, N.M.3
Lesterhuis, W.J.4
Diepstra, J.H.5
van Muijen, G.N.6
Strijk, S.P.7
Ruers, T.J.8
Boerman, O.C.9
Oyen, W.J.10
-
132
-
-
0032918091
-
Migration of human dendritic cells after injection in patients with metastatic malignancies
-
Morse, M.A.; Coleman, R.E.; Akabani, G.; Niehaus, N.; Coleman, D.; Lyerly, H.K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 1999, 59, 56-58.
-
(1999)
Cancer Res.
, vol.59
, pp. 56-58
-
-
Morse, M.A.1
Coleman, R.E.2
Akabani, G.3
Niehaus, N.4
Coleman, D.5
Lyerly, H.K.6
-
133
-
-
77955261234
-
CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells
-
Yewdall, A.W.; Drutman, S.B.; Jinwala, F.; Bahjat, K.S.; Bhardwaj, N. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One 2010, 5, e11144.
-
(2010)
PLoS One
, vol.5
-
-
Yewdall, A.W.1
Drutman, S.B.2
Jinwala, F.3
Bahjat, K.S.4
Bhardwaj, N.5
-
134
-
-
33645325115
-
DCs study group of the DeCOG. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed DCs (DCs) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DCs study group of the DeCOG
-
Schadendorf, D.; Ugurel, S.; Schuler-Thurner, B.; Nestle, F.O.; Enk, A.; Bröcker, E.B.; Grabbe, S.; Rittgen, W.; Edler, L.; Sucker, A.; et al. DCs study group of the DeCOG. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed DCs (DCs) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DCs study group of the DeCOG. Ann. Oncol. 2006, 17, 563-570.
-
(2006)
Ann. Oncol.
, vol.17
, pp. 563-570
-
-
Schadendorf, D.1
Ugurel, S.2
Schuler-Thurner, B.3
Nestle, F.O.4
Enk, A.5
Bröcker, E.B.6
Grabbe, S.7
Rittgen, W.8
Edler, L.9
Sucker, A.10
-
135
-
-
0034554863
-
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
-
Small, E.J.; Fratesi, P.; Reese, D.M.; Strang, G.; Laus, R.; Peshwa, M.V.; Valone, F.H. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 2000, 18, 3894-3903.
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 3894-3903
-
-
Small, E.J.1
Fratesi, P.2
Reese, D.M.3
Strang, G.4
Laus, R.5
Peshwa, M.V.6
Valone, F.H.7
-
136
-
-
68549135290
-
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
-
Higano, C.S.; Schellhammer, P.F.; Small, E.J.; Burch, P.A.; Nemunaitis, J.; Yuh, L.; Provost, N.; Frohlich, M.W. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115, 3670-3679.
-
(2009)
Cancer
, vol.115
, pp. 3670-3679
-
-
Higano, C.S.1
Schellhammer, P.F.2
Small, E.J.3
Burch, P.A.4
Nemunaitis, J.5
Yuh, L.6
Provost, N.7
Frohlich, M.W.8
-
137
-
-
23044479028
-
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T cell responses modulated by the local central nervous system tumor micro-environment
-
Liau, L.M.; Prins, R.M.; Kiertscher, S.M.; Odesa, S.K.; Kremen, T.J.; Giovannone, A.J.; Lin, J.W.; Chute, D.J.; Mischel, P.S.; Cloughesy, T.F.; et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T cell responses modulated by the local central nervous system tumor micro-environment. Clin. Cancer Res. 2005, 11, 5515-5525.
-
(2005)
Clin. Cancer Res.
, vol.11
, pp. 5515-5525
-
-
Liau, L.M.1
Prins, R.M.2
Kiertscher, S.M.3
Odesa, S.K.4
Kremen, T.J.5
Giovannone, A.J.6
Lin, J.W.7
Chute, D.J.8
Mischel, P.S.9
Cloughesy, T.F.10
-
138
-
-
0030934973
-
Decreased antigen presentation by dendritic cells in patients with breast cancer
-
Gabrilovich, D.I.; Corak, J.; Ciernik, I.F.; Kavanaugh, D.; Carbone, D.P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 1997, 3, 483-490.
-
(1997)
Clin. Cancer Res.
, vol.3
, pp. 483-490
-
-
Gabrilovich, D.I.1
Corak, J.2
Ciernik, I.F.3
Kavanaugh, D.4
Carbone, D.P.5
-
139
-
-
2542421141
-
Dendritic cells are dysfunctional in patients with operable breast cancer
-
Satthaporn, S.; Robins, A.; Vassanasiri, W.; El-Sheemy, M.; Jibril, J.A.; Clark, D.; Valerio, D.; Eremin, O. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol. Immunother. 2004, 53, 510-518.
-
(2004)
Cancer Immunol. Immunother.
, vol.53
, pp. 510-518
-
-
Satthaporn, S.1
Robins, A.2
Vassanasiri, W.3
El-Sheemy, M.4
Jibril, J.A.5
Clark, D.6
Valerio, D.7
Eremin, O.8
-
140
-
-
79955947379
-
The renaissance of interferon therapy for the treatment of myeloid malignancies
-
Kiladjian, J.J.; Mesa, R.A.; Hoffman, R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011, 117, 4706-4715.
-
(2011)
Blood
, vol.117
, pp. 4706-4715
-
-
Kiladjian, J.J.1
Mesa, R.A.2
Hoffman, R.3
-
141
-
-
77954242369
-
The chase for the RIG-I ligand-Recent advances
-
Schlee, M.; Hartmann, G. The chase for the RIG-I ligand-Recent advances. Mol. Ther. 2010, 18, 1254-1262.
-
(2010)
Mol. Ther.
, vol.18
, pp. 1254-1262
-
-
Schlee, M.1
Hartmann, G.2
-
142
-
-
0141886220
-
IFN-α skews monocyte differentiation into Toll like receptor 7-expressing dendritic cells with potent functional activities
-
Mohty, M.; Vialle-Castellano, A.; Nunes, J.A.; Isnardon, D.; Olive, D.; Gaugler, B. IFN-α skews monocyte differentiation into Toll like receptor 7-expressing dendritic cells with potent functional activities. J. Immunol. 2003, 171, 3385-3393.
-
(2003)
J. Immunol.
, vol.171
, pp. 3385-3393
-
-
Mohty, M.1
Vialle-Castellano, A.2
Nunes, J.A.3
Isnardon, D.4
Olive, D.5
Gaugler, B.6
-
143
-
-
0034658658
-
Type 1 interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice
-
Santini, S.M.; Lapenta, C.; Logozzi, M.; Parlato, S.; Spada, M.; di Pucchio, T.; Belardelli, F. Type 1 interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 2000, 191, 1777-1788.
-
(2000)
J. Exp. Med.
, vol.191
, pp. 1777-1788
-
-
Santini, S.M.1
Lapenta, C.2
Logozzi, M.3
Parlato, S.4
Spada, M.5
di Pucchio, T.6
Belardelli, F.7
-
144
-
-
84960987965
-
Pouvoir immunisant du virus vaccinal inactivé par des rayons ultraviolets
-
Nagano, Y.; Kojima, Y. Pouvoir immunisant du virus vaccinal inactivé par des rayons ultraviolets. C. R. Seances. Soc. Biol. Fil. 1954, 148, 1700-1702.
-
(1954)
C. R. Seances. Soc. Biol. Fil.
, vol.148
, pp. 1700-1702
-
-
Nagano, Y.1
Kojima, Y.2
-
145
-
-
0010973695
-
Studies on the production, mode of action and properties of interferon
-
Lindenmann, J.; Burke, D.C.; Isaacs, A. Studies on the production, mode of action and properties of interferon. Br. J. Exp. Pathol. 1957, 38, 551-562.
-
(1957)
Br. J. Exp. Pathol.
, vol.38
, pp. 551-562
-
-
Lindenmann, J.1
Burke, D.C.2
Isaacs, A.3
-
146
-
-
0035900481
-
Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus
-
Blanco, P.; Palucka, A.K.; Gill, M.; Pascual, V.; Banchereau, J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 2001, 294, 1540-1543.
-
(2001)
Science
, vol.294
, pp. 1540-1543
-
-
Blanco, P.1
Palucka, A.K.2
Gill, M.3
Pascual, V.4
Banchereau, J.5
-
147
-
-
0032695108
-
Natural adjuvants: Endogenous activators of dendritic cells
-
Gallucci, S.; Lolkema, M.; Matzinger, P. Natural adjuvants: Endogenous activators of dendritic cells. Nat. Med. 1999, 5, 1249-1255.
-
(1999)
Nat. Med.
, vol.5
, pp. 1249-1255
-
-
Gallucci, S.1
Lolkema, M.2
Matzinger, P.3
-
148
-
-
0035284744
-
Differential regulation of human blood dendritic cell subsets by IFNs
-
Ito, T.; Amakawa, R.; Inaba, M.; Ikehara, S.; Inaba, K.; Fukuhara, S. Differential regulation of human blood dendritic cell subsets by IFNs. J. Immunol. 2001, 166, 2961-2969.
-
(2001)
J. Immunol.
, vol.166
, pp. 2961-2969
-
-
Ito, T.1
Amakawa, R.2
Inaba, M.3
Ikehara, S.4
Inaba, K.5
Fukuhara, S.6
-
149
-
-
0031656896
-
Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells
-
Paquette, R.L.; Hsu, N.C.; Kiertscher, S.M.; Park, A.N.; Tran, L.; Roth, M.D.; Glaspy, J.A. Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol. 1998, 64, 358-367.
-
(1998)
J. Leukoc. Biol.
, vol.64
, pp. 358-367
-
-
Paquette, R.L.1
Hsu, N.C.2
Kiertscher, S.M.3
Park, A.N.4
Tran, L.5
Roth, M.D.6
Glaspy, J.A.7
-
150
-
-
0142092614
-
Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon
-
Le Bon, A.; Etchart, N.; Rossmann, C.; Ashton, M.; Hou, S.; Gewert, D.; Borrow, P.; Tough, D.F. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 2003, 4, 1009-1015.
-
(2003)
Nat. Immunol.
, vol.4
, pp. 1009-1015
-
-
Le Bon, A.1
Etchart, N.2
Rossmann, C.3
Ashton, M.4
Hou, S.5
Gewert, D.6
Borrow, P.7
Tough, D.F.8
-
151
-
-
0033081259
-
Type I interferons keep activated T cells alive
-
Marrack, P.; Kappler, J.; Mitchell, T. Type I interferons keep activated T cells alive. J. Exp. Med. 1999, 189, 521-530.
-
(1999)
J. Exp. Med.
, vol.189
, pp. 521-530
-
-
Marrack, P.1
Kappler, J.2
Mitchell, T.3
-
152
-
-
4644368384
-
Frontline: Absence of functional STAT4 activation despite detectable tyrosine phosphorylation induced by murine IFN-α
-
Berenson, L.S.; Farrar, J.D.; Murphy, T.L.; Murphy, K.M. Frontline: Absence of functional STAT4 activation despite detectable tyrosine phosphorylation induced by murine IFN-α. Eur. J. Immunol. 2004, 34, 2365-2374.
-
(2004)
Eur. J. Immunol.
, vol.34
, pp. 2365-2374
-
-
Berenson, L.S.1
Farrar, J.D.2
Murphy, T.L.3
Murphy, K.M.4
-
153
-
-
35748967291
-
IFN-α is not sufficient to drive Thl development due to lack of stable T-bet expression
-
Ramos, H.J.; Davis, A.M.; George, T.C.; Farrar, J.D. IFN-α is not sufficient to drive Thl development due to lack of stable T-bet expression. J. Immunol. 2007, 179, 3792-3803.
-
(2007)
J. Immunol.
, vol.179
, pp. 3792-3803
-
-
Ramos, H.J.1
Davis, A.M.2
George, T.C.3
Farrar, J.D.4
-
154
-
-
33750321707
-
Interferons, immunity and cancer immunoediting
-
Dunn, G.P.; Koebel, C.M.; Schreiber, R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006, 6, 836-848.
-
(2006)
Nat. Rev. Immunol.
, vol.6
, pp. 836-848
-
-
Dunn, G.P.1
Koebel, C.M.2
Schreiber, R.D.3
-
155
-
-
19344365408
-
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent
-
De Visser, K.E.; Korets, L.V.; Coussens, L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005, 7, 411-423.
-
(2005)
Cancer Cell
, vol.7
, pp. 411-423
-
-
De Visser, K.E.1
Korets, L.V.2
Coussens, L.M.3
-
156
-
-
47949096781
-
Cancer-related inflammation
-
Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436-444.
-
(2008)
Nature
, vol.454
, pp. 436-444
-
-
Mantovani, A.1
Allavena, P.2
Sica, A.3
Balkwill, F.4
-
157
-
-
0027433104
-
Interteron-α increases the frequency interferon γ-producing human CD4+ T cells
-
Brinkmann, V.; Geiger, T.; Alkan, S.; Heusser, C.H. Interteron-α increases the frequency interferon γ-producing human CD4+ T cells. J. Exp. Med. 1993, 178, 1655-1663.
-
(1993)
J. Exp. Med.
, vol.178
, pp. 1655-1663
-
-
Brinkmann, V.1
Geiger, T.2
Alkan, S.3
Heusser, C.H.4
-
158
-
-
0029671118
-
Roles of IFN-α and IFN-β in IL-12-induced T helper cell-1 development
-
Wenner, C.A.; Guler, M.L.; Macatonia, S.E.; O'Garra, A.; Murphy, K.M. Roles of IFN-α and IFN-β in IL-12-induced T helper cell-1 development. J. Immunol. 1996, 156, 1442-1447.
-
(1996)
J. Immunol.
, vol.156
, pp. 1442-1447
-
-
Wenner, C.A.1
Guler, M.L.2
McAtonia, S.E.3
O'Garra, A.4
Murphy, K.M.5
-
159
-
-
0030036342
-
Induction of bystander T cell proliferation by viruses and type I interferon in vivo
-
Tough, D.F.; Borrow, P.; Sprent, J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996, 272, 1947-1950.
-
(1996)
Science
, vol.272
, pp. 1947-1950
-
-
Tough, D.F.1
Borrow, P.2
Sprent, J.3
-
160
-
-
5144225454
-
Therapeutic cancer vaccines: Using unique antigens
-
Lewis, J.J. Therapeutic cancer vaccines: Using unique antigens. Proc. Natl. Acad. Sci. USA 2004, 101, 14653-14656.
-
(2004)
Proc. Natl. Acad. Sci. USA
, vol.101
, pp. 14653-14656
-
-
Lewis, J.J.1
-
161
-
-
33846935228
-
Unique human tumor antigens: Immunobiology and use in clinical trials
-
Parmiani, G.; de Filippo, A.; Novellino, L.; Castelli, C. Unique human tumor antigens: Immunobiology and use in clinical trials. J. Immunol. 2007, 178, 1975-1979.
-
(2007)
J. Immunol.
, vol.178
, pp. 1975-1979
-
-
Parmiani, G.1
de Filippo, A.2
Novellino, L.3
Castelli, C.4
-
162
-
-
44949154503
-
CD8+ T cell efficacy in vaccination and disease
-
Appay, V.; Douek, D.C.; Price, D.A. CD8+ T cell efficacy in vaccination and disease. Nat. Med. 2008, 14, 623-628.
-
(2008)
Nat. Med.
, vol.14
, pp. 623-628
-
-
Appay, V.1
Douek, D.C.2
Price, D.A.3
-
163
-
-
56449097201
-
Type 2 bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells
-
Minkis, K.; Kavanagh, D.G.; Alter, G.; Bogunovic, D.; O'Neill, D.; Adams, S.; Pavlick, A.B.; Walker, D.; Brockman, M.A.; Gandhi, R.T.; et al. Type 2 bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res. 2008, 68, 9441-9450.
-
(2008)
Cancer Res.
, vol.68
, pp. 9441-9450
-
-
Minkis, K.1
Kavanagh, D.G.2
Alter, G.3
Bogunovic, D.4
O'Neill, D.5
Adams, S.6
Pavlick, A.B.7
Walker, D.8
Brockman, M.A.9
Gandhi, R.T.10
-
164
-
-
34249000341
-
Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development
-
Aspord, C.; Pedroza-Gonzalez, A.; Gallegos, M.; Tindle, S.; Burton, E.C.; Su, D.; Marches, F.; Banchereau, J.; Palucka, A.K. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J. Exp. Med. 2007, 204, 1037-1047.
-
(2007)
J. Exp. Med.
, vol.204
, pp. 1037-1047
-
-
Aspord, C.1
Pedroza-Gonzalez, A.2
Gallegos, M.3
Tindle, S.4
Burton, E.C.5
Su, D.6
Marches, F.7
Banchereau, J.8
Palucka, A.K.9
-
165
-
-
0033198562
-
The makings of a tumor rejection antigen
-
Gilboa, E. The makings of a tumor rejection antigen. Immunity 1999, 11, 263-270.
-
(1999)
Immunity
, vol.11
, pp. 263-270
-
-
Gilboa, E.1
-
166
-
-
29144524877
-
Professional type I interferon-producing cells-A unique subpopulation of dendritic cells
-
Magyarics, Z.; Rajnavölgyi, E. Professional type I interferon-producing cells-A unique subpopulation of dendritic cells. Acta. Microbiol. Immunol. Hung. 2005, 52, 443-462.
-
(2005)
Acta. Microbiol. Immunol. Hung.
, vol.52
, pp. 443-462
-
-
Magyarics, Z.1
Rajnavölgyi, E.2
-
167
-
-
32944464648
-
Pathogen recognition and innate immunity
-
Akira, S.; Uematsu, S.; Takeuchi, O. Pathogen recognition and innate immunity. Cell 2006, 124, 783-801.
-
(2006)
Cell
, vol.124
, pp. 783-801
-
-
Akira, S.1
Uematsu, S.2
Takeuchi, O.3
-
168
-
-
20044382430
-
Toll-like receptor 3 promotes cross-priming to virus-infected cells
-
Schulz, O.; Diebold, S.S.; Chen, M.; Näslund, T.I.; Nolte, M.A.; Alexopoulou, L.; Azuma, Y.T.; Flavell, R.A.; Liljeström, P.; Reis e Sousa, C. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005, 433, 887-892.
-
(2005)
Nature
, vol.433
, pp. 887-892
-
-
Schulz, O.1
Diebold, S.S.2
Chen, M.3
Näslund, T.I.4
Nolte, M.A.5
Alexopoulou, L.6
Azuma, Y.T.7
Flavell, R.A.8
Liljeström, P.9
Reis e Sousa, C.10
-
169
-
-
70350049934
-
Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
-
Fournier, P.; Arnold, A.; Schirrmacher, V. Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus. J. BUON 2009, 14, 111-122.
-
(2009)
J. BUON
, vol.14
, pp. 111-122
-
-
Fournier, P.1
Arnold, A.2
Schirrmacher, V.3
-
170
-
-
33947111517
-
Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines
-
Kalinski, P.; Nakamura, Y.; Watchmaker, P.; Giermasz, A.; Muthuswamy, R.; Mailliard, R.B. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol. Res. 2006, 36, 137-146.
-
(2006)
Immunol. Res.
, vol.36
, pp. 137-146
-
-
Kalinski, P.1
Nakamura, Y.2
Watchmaker, P.3
Giermasz, A.4
Muthuswamy, R.5
Mailliard, R.B.6
-
171
-
-
33646400810
-
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-α results in the activation of specific CD8+T cells and monocyte/dendritic cell precursors
-
Di Pucchio, T.; Pilla, L.; Capone, I.; Ferrantini, M.; Montefiore, E.; Urbani, F.; Patuzzo, R.; Pennacchioli, E.; Santinami, M.; Cova, A.; et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-α results in the activation of specific CD8+T cells and monocyte/dendritic cell precursors. Cancer Res. 2006, 66, 4943-4951.
-
(2006)
Cancer Res.
, vol.66
, pp. 4943-4951
-
-
Di Pucchio, T.1
Pilla, L.2
Capone, I.3
Ferrantini, M.4
Montefiore, E.5
Urbani, F.6
Patuzzo, R.7
Pennacchioli, E.8
Santinami, M.9
Cova, A.10
-
172
-
-
23444439371
-
Delivery of dendritic cells engineered to secrete IFN-α into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: Dependence on apoptotic pathways
-
Kuwashima, N.; Nishimura, F.; Eguchi, J.; Sato, H.; Hatano, M.; Tsugawa, T.; Sakaida, T.; Dusak, J.E.; Fellows-Mayle, W.K.; Papworth, G.D.; et al. Delivery of dendritic cells engineered to secrete IFN-α into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: Dependence on apoptotic pathways. J. Immunol. 2005, 175, 2730-2740.
-
(2005)
J. Immunol.
, vol.175
, pp. 2730-2740
-
-
Kuwashima, N.1
Nishimura, F.2
Eguchi, J.3
Sato, H.4
Hatano, M.5
Tsugawa, T.6
Sakaida, T.7
Dusak, J.E.8
Fellows-Mayle, W.K.9
Papworth, G.D.10
-
173
-
-
0037016729
-
Molecular cross-talk between the TRAIL and interferon signalling pathways
-
Kumar-Sinha, C.; Varambally, S.; Sreekumar, A.; Chinnaiyan, A.M. Molecular cross-talk between the TRAIL and interferon signalling pathways. J. Biol. Chem. 2002, 277, 575-585.
-
(2002)
J. Biol. Chem.
, vol.277
, pp. 575-585
-
-
Kumar-Sinha, C.1
Varambally, S.2
Sreekumar, A.3
Chinnaiyan, A.M.4
-
174
-
-
0030892136
-
Selective expression of an interleukin-12 receptor component by human T helper 1 cells
-
Rogge, L.; Barberis-Maino, L.; Biffi, M.; Passini, N.; Presky, D.H.; Gubler Sinigaglia, E. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med. 1997, 185, 825-831.
-
(1997)
J. Exp. Med.
, vol.185
, pp. 825-831
-
-
Rogge, L.1
Barberis-Maino, L.2
Biffi, M.3
Passini, N.4
Presky, D.H.5
Gubler Sinigaglia, E.6
-
175
-
-
0842301509
-
Type 1 interferon as a link between innate and adaptive immunity through dendritic cell stimulation
-
Tough, D.F. Type 1 interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk. Lymphoma 2004, 45, 257-264.
-
(2004)
Leuk. Lymphoma
, vol.45
, pp. 257-264
-
-
Tough, D.F.1
-
176
-
-
0035139983
-
Danger signals: SOS to the immune system
-
Gallucci, S.; Matzinger, P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 2001, 13, 114-119.
-
(2001)
Curr. Opin. Immunol.
, vol.13
, pp. 114-119
-
-
Gallucci, S.1
Matzinger, P.2
-
177
-
-
2442707774
-
Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4
-
Cisco, R.M.; Abdel-Wahab, Z.; Dannull, J.; Nair, S.; Tyler, D.S.; Gilboa, E.; Vieweg, J.; Daaka, Y.; Pruitt, S.K. Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. J. Immunol. 2004, 172, 7162-7168.
-
(2004)
J. Immunol.
, vol.172
, pp. 7162-7168
-
-
Cisco, R.M.1
Abdel-Wahab, Z.2
Dannull, J.3
Nair, S.4
Tyler, D.S.5
Gilboa, E.6
Vieweg, J.7
Daaka, Y.8
Pruitt, S.K.9
-
178
-
-
44349173032
-
Enhancing the T cell stimulatory capacity of human dendritic cells by coelectroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA
-
Bonehill, A.; Tuyaerts, S.; van Nuffel, A.M.; Heirman, C.; Bos, T.J.; Fostier, K.; Neyns, B.; Thielemans, K. Enhancing the T cell stimulatory capacity of human dendritic cells by coelectroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol. Ther. 2008, 16, 1170-1180.
-
(2008)
Mol. Ther.
, vol.16
, pp. 1170-1180
-
-
Bonehill, A.1
Tuyaerts, S.2
van Nuffel, A.M.3
Heirman, C.4
Bos, T.J.5
Fostier, K.6
Neyns, B.7
Thielemans, K.8
-
179
-
-
84857185580
-
Newcastle disease virus induces pro-inflammatory conditions and type 1 interferon for counter-acting Treg activity
-
Fournier, P.; Arnold, A.; Wilden, H.; Schirrmacher, V. Newcastle disease virus induces pro-inflammatory conditions and type 1 interferon for counter-acting Treg activity. Int. J. Oncol. 2012, 40, 840-850.
-
(2012)
Int. J. Oncol.
, vol.40
, pp. 840-850
-
-
Fournier, P.1
Arnold, A.2
Wilden, H.3
Schirrmacher, V.4
-
180
-
-
33846432377
-
Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells
-
Kurooka, M.; Kaneda, Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res. 2007, 67, 227-236.
-
(2007)
Cancer Res.
, vol.67
, pp. 227-236
-
-
Kurooka, M.1
Kaneda, Y.2
-
181
-
-
33646490015
-
Role of natural killer cell function in dendritic cell-based vaccines
-
66-65
-
Woo, C.Y.; Clay, T.M.; Lyerly, H.K.; Morse, M.A.; Osada, T. Role of natural killer cell function in dendritic cell-based vaccines. Expert Rev. Vaccines 2006, 5, 66-65.
-
(2006)
Expert Rev. Vaccines
, vol.5
-
-
Woo, C.Y.1
Clay, T.M.2
Lyerly, H.K.3
Morse, M.A.4
Osada, T.5
-
182
-
-
77956384935
-
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination
-
Van Tendeloo, V.F.; van de Velde, A.; van Driessche, A.; Cools, N.; Anguille, S.; Ladell, K.; Gostick, E.; Vermeulen, K.; Pieters, K.; Nijs, G.; et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl. Acad. Sci. USA 2010, 107, 13824-13829.
-
(2010)
Proc. Natl. Acad. Sci. USA
, vol.107
, pp. 13824-13829
-
-
Van Tendeloo, V.F.1
van de Velde, A.2
van Driessche, A.3
Cools, N.4
Anguille, S.5
Ladell, K.6
Gostick, E.7
Vermeulen, K.8
Pieters, K.9
Nijs, G.10
-
183
-
-
34848827471
-
Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection
-
Ebihara, T.; Masuda, H.; Akazawa, T.; Shingai, M.; Kikuta, H.; Ariga, T.; Matsumoto, M.; Seya, T. Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection. Int. Immunol. 2007, 19, 1145-1155.
-
(2007)
Int. Immunol.
, vol.19
, pp. 1145-1155
-
-
Ebihara, T.1
Masuda, H.2
Akazawa, T.3
Shingai, M.4
Kikuta, H.5
Ariga, T.6
Matsumoto, M.7
Seya, T.8
-
184
-
-
77950600175
-
Danger signals in tumor cells: A risk factor for autoimmune disease?
-
Schirrmacher, V.; Fournier, P. Danger signals in tumor cells: A risk factor for autoimmune disease? Expert Rev. Vaccines 2010, 9, 347-350.
-
(2010)
Expert Rev. Vaccines
, vol.9
, pp. 347-350
-
-
Schirrmacher, V.1
Fournier, P.2
-
185
-
-
72849135966
-
The Oncolytic Activity of Newcastle Disease Virus NDV-HUJ on Chemoresistant Primary Melanoma Cells Is Dependent on the Proapoptotic Activity of the Inhibitor of Apoptosis Protein Livin
-
Lazar, I.; Yaacov, B.; Shiloach, T.; Eliahoo, E.; Kadouri, L.; Lotem, M.; Perlman, R.; Zakay-Rones, Z.; Panet, A.; Ben-Yehuda, D. The Oncolytic Activity of Newcastle Disease Virus NDV-HUJ on Chemoresistant Primary Melanoma Cells Is Dependent on the Proapoptotic Activity of the Inhibitor of Apoptosis Protein Livin. J. Virol. 2010, 84, 639-646.
-
(2010)
J. Virol.
, vol.84
, pp. 639-646
-
-
Lazar, I.1
Yaacov, B.2
Shiloach, T.3
Eliahoo, E.4
Kadouri, L.5
Lotem, M.6
Perlman, R.7
Zakay-Rones, Z.8
Panet, A.9
Ben-Yehuda, D.10
-
186
-
-
77950482295
-
Type I Interferon-Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy
-
Elankumaran, S.; Chavan, V.; Qiao, D.; Shobana, R.; Moorkanat, G.; Biswas, M.; Samal, S.K. Type I Interferon-Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy. J. Virol. 2010, 84, 3835-3844.
-
(2010)
J. Virol.
, vol.84
, pp. 3835-3844
-
-
Elankumaran, S.1
Chavan, V.2
Qiao, D.3
Shobana, R.4
Moorkanat, G.5
Biswas, M.6
Samal, S.K.7
-
187
-
-
77951076912
-
Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus
-
Puhlmann, J.; Puehler, F.; Mumberg, D.; Boukamp, P.; Beier, R. Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Oncogene 2010, 29, 2205-2216.
-
(2010)
Oncogene
, vol.29
, pp. 2205-2216
-
-
Puhlmann, J.1
Puehler, F.2
Mumberg, D.3
Boukamp, P.4
Beier, R.5
-
188
-
-
79958119977
-
Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells
-
Mansour, M.; Palese, P.; Zamarin, D. Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells. J. Virol. 2011, 85, 6015-6023.
-
(2011)
J. Virol.
, vol.85
, pp. 6015-6023
-
-
Mansour, M.1
Palese, P.2
Zamarin, D.3
|